Is haploinsufficiency a sufficient mechanism for MYBPC3 truncating mutations?

Area of Science:

• Cardiology
• Molecular Biology
• Genetics

Background:

• Hypertrophic cardiomyopathy (HCM) is a genetic heart disease often caused by mutations in sarcomeric proteins.
• MYBPC3 mutations are a common cause of HCM, but the precise molecular mechanisms leading to cardiac dysfunction remain incompletely understood.

Purpose of the Study:

• To investigate the temporal relationship between MYBPC3 gene expression and cardiac protein levels in human cell culture models.
• To determine if reduced MYBPC3 expression precedes or follows changes in cMyBP-C protein levels during early cardiac dysfunction.

Main Methods:

• Utilized human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
• Assessed MYBPC3 mRNA and cMyBP-C protein expression levels over time.
• Evaluated functional cardiac parameters in response to altered MYBPC3 expression.

Main Results:

• Observed a significant decrease in MYBPC3 gene expression prior to any detectable reduction in cMyBP-C protein levels.
• Early reduction in MYBPC3 expression was correlated with initial signs of cellular dysfunction.
• These findings suggest a direct impact of MYBPC3 gene dosage on cardiomyocyte function.

Conclusions:

• Reduced MYBPC3 gene expression is an early molecular event that precedes cMyBP-C protein reduction and contributes to cardiac dysfunction.
• This highlights the importance of monitoring MYBPC3 gene expression in the context of inherited cardiomyopathies.
• The study provides a new perspective on the pathogenic cascade initiated by MYBPC3 mutations.